Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 33 | 2024 | 2421 | 4.080 |
Why?
|
| Heart Transplantation | 23 | 2023 | 894 | 1.760 |
Why?
|
| Heart-Assist Devices | 20 | 2023 | 1093 | 1.590 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 36 | 1.310 |
Why?
|
| Water-Electrolyte Imbalance | 3 | 2023 | 79 | 1.040 |
Why?
|
| Diuretics | 4 | 2022 | 169 | 1.030 |
Why?
|
| Cardiomyopathies | 8 | 2023 | 514 | 0.940 |
Why?
|
| Child | 58 | 2025 | 25734 | 0.900 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2022 | 32 | 0.900 |
Why?
|
| Hospitalization | 7 | 2024 | 1892 | 0.890 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2021 | 145 | 0.880 |
Why?
|
| Shock, Cardiogenic | 3 | 2024 | 211 | 0.820 |
Why?
|
| Heart Defects, Congenital | 7 | 2023 | 1874 | 0.800 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 254 | 0.780 |
Why?
|
| Hyponatremia | 2 | 2023 | 76 | 0.670 |
Why?
|
| Retrospective Studies | 39 | 2024 | 17380 | 0.630 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 26 | 0.600 |
Why?
|
| Creatinine | 2 | 2018 | 429 | 0.580 |
Why?
|
| Infant | 28 | 2025 | 13159 | 0.580 |
Why?
|
| Child, Preschool | 31 | 2025 | 14789 | 0.580 |
Why?
|
| Hospital Mortality | 7 | 2024 | 1088 | 0.560 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2019 | 640 | 0.560 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 548 | 0.540 |
Why?
|
| Cardiotonic Agents | 4 | 2019 | 144 | 0.540 |
Why?
|
| Acute Kidney Injury | 6 | 2025 | 696 | 0.510 |
Why?
|
| Anemia | 2 | 2018 | 351 | 0.490 |
Why?
|
| Adolescent | 34 | 2025 | 20505 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2019 | 342 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2014 | 381 | 0.470 |
Why?
|
| Mortality | 1 | 2016 | 262 | 0.450 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 91 | 0.450 |
Why?
|
| Hospitals, Pediatric | 7 | 2018 | 789 | 0.450 |
Why?
|
| Humans | 69 | 2025 | 133414 | 0.450 |
Why?
|
| Male | 48 | 2025 | 65692 | 0.420 |
Why?
|
| Female | 46 | 2025 | 71463 | 0.400 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2014 | 266 | 0.360 |
Why?
|
| Graft Rejection | 10 | 2023 | 628 | 0.340 |
Why?
|
| Cohort Studies | 12 | 2021 | 5176 | 0.330 |
Why?
|
| Treatment Outcome | 20 | 2023 | 12974 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 765 | 0.310 |
Why?
|
| Acute Disease | 5 | 2023 | 1190 | 0.310 |
Why?
|
| Risk Factors | 12 | 2024 | 11085 | 0.310 |
Why?
|
| Prognosis | 8 | 2023 | 5074 | 0.300 |
Why?
|
| Cardiology | 1 | 2014 | 521 | 0.300 |
Why?
|
| Infant, Newborn | 13 | 2021 | 8586 | 0.290 |
Why?
|
| Heart Arrest | 2 | 2014 | 376 | 0.280 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 24 | 0.280 |
Why?
|
| Young Adult | 10 | 2023 | 9854 | 0.280 |
Why?
|
| Time Factors | 9 | 2020 | 6570 | 0.280 |
Why?
|
| Registries | 5 | 2021 | 1569 | 0.270 |
Why?
|
| Heart Rate | 3 | 2025 | 600 | 0.260 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 266 | 0.250 |
Why?
|
| Electrocardiography | 3 | 2025 | 1005 | 0.250 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 100 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 226 | 0.250 |
Why?
|
| Milrinone | 1 | 2006 | 31 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 252 | 0.250 |
Why?
|
| Hemodynamics | 3 | 2025 | 868 | 0.250 |
Why?
|
| Pediatrics | 2 | 2019 | 1216 | 0.240 |
Why?
|
| Incidence | 6 | 2018 | 3396 | 0.240 |
Why?
|
| Hemodynamic Monitoring | 1 | 2025 | 16 | 0.240 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 178 | 0.240 |
Why?
|
| Critical Illness | 4 | 2025 | 624 | 0.230 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 793 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2020 | 414 | 0.230 |
Why?
|
| Adult | 12 | 2024 | 31787 | 0.230 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 82 | 0.220 |
Why?
|
| Sodium | 2 | 2023 | 308 | 0.220 |
Why?
|
| Dopamine | 1 | 2006 | 284 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2020 | 3696 | 0.220 |
Why?
|
| Length of Stay | 4 | 2019 | 1381 | 0.220 |
Why?
|
| Arginine Vasopressin | 1 | 2004 | 29 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2009 | 1152 | 0.220 |
Why?
|
| Kidney Diseases | 1 | 2008 | 505 | 0.210 |
Why?
|
| Myocarditis | 3 | 2015 | 137 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 3083 | 0.200 |
Why?
|
| Ambulatory Care | 1 | 2006 | 413 | 0.200 |
Why?
|
| Texas | 6 | 2016 | 3688 | 0.200 |
Why?
|
| Chlorides | 1 | 2022 | 108 | 0.190 |
Why?
|
| Developmental Disabilities | 1 | 2007 | 733 | 0.190 |
Why?
|
| Hypernatremia | 1 | 2023 | 33 | 0.190 |
Why?
|
| Flecainide | 1 | 2002 | 23 | 0.190 |
Why?
|
| Sotalol | 1 | 2002 | 34 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2016 | 1241 | 0.190 |
Why?
|
| Transferrin | 1 | 2021 | 50 | 0.190 |
Why?
|
| Hypotension | 2 | 2022 | 191 | 0.180 |
Why?
|
| Thrombosis | 2 | 2022 | 539 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2019 | 1488 | 0.180 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2002 | 111 | 0.170 |
Why?
|
| Syndrome | 3 | 2009 | 1158 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 39 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 227 | 0.170 |
Why?
|
| North America | 1 | 2020 | 260 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 138 | 0.160 |
Why?
|
| Patient Admission | 2 | 2014 | 191 | 0.160 |
Why?
|
| Comorbidity | 3 | 2020 | 1615 | 0.150 |
Why?
|
| Age Factors | 5 | 2020 | 2984 | 0.150 |
Why?
|
| Overweight | 1 | 2021 | 383 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 56 | 0.150 |
Why?
|
| Postoperative Complications | 6 | 2016 | 3155 | 0.150 |
Why?
|
| Iron | 1 | 2021 | 304 | 0.150 |
Why?
|
| Age of Onset | 1 | 2020 | 636 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 536 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 201 | 0.140 |
Why?
|
| United States | 7 | 2021 | 11677 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2016 | 1159 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 234 | 0.140 |
Why?
|
| Heart Ventricles | 2 | 2019 | 799 | 0.140 |
Why?
|
| Medical Records | 2 | 2016 | 193 | 0.130 |
Why?
|
| American Heart Association | 1 | 2019 | 328 | 0.130 |
Why?
|
| Echocardiography | 2 | 2018 | 1124 | 0.130 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 16 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2009 | 158 | 0.120 |
Why?
|
| Hypertrophy | 1 | 2016 | 104 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 689 | 0.120 |
Why?
|
| Hospital Charges | 1 | 2015 | 63 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2016 | 321 | 0.110 |
Why?
|
| Patient Discharge | 2 | 2020 | 517 | 0.110 |
Why?
|
| Disease Progression | 3 | 2016 | 2237 | 0.110 |
Why?
|
| Cardiac Catheterization | 3 | 2023 | 664 | 0.110 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 33 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 749 | 0.110 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 57 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2014 | 54 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 916 | 0.110 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2014 | 44 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 2087 | 0.110 |
Why?
|
| Graft Survival | 4 | 2021 | 557 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2025 | 6570 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 1336 | 0.100 |
Why?
|
| Prevalence | 2 | 2018 | 2651 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2019 | 216 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 207 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2006 | 530 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2015 | 406 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 237 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 3424 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1128 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1850 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 121 | 0.090 |
Why?
|
| Candidiasis | 1 | 2013 | 138 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1334 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2019 | 792 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1252 | 0.090 |
Why?
|
| Colloids | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 331 | 0.080 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 36 | 0.080 |
Why?
|
| Kidney | 2 | 2023 | 1416 | 0.080 |
Why?
|
| Natriuretic Agents | 1 | 2009 | 33 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2008 | 2294 | 0.080 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 85 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 544 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2011 | 289 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2021 | 1709 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 571 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 137 | 0.070 |
Why?
|
| Consanguinity | 1 | 2007 | 118 | 0.070 |
Why?
|
| Cachexia | 1 | 2007 | 53 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2007 | 56 | 0.070 |
Why?
|
| Electromyography | 1 | 2007 | 177 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1139 | 0.070 |
Why?
|
| Patient Selection | 2 | 2010 | 732 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2006 | 30 | 0.060 |
Why?
|
| Systole | 1 | 2006 | 206 | 0.060 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2008 | 242 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 162 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 5455 | 0.060 |
Why?
|
| Leukopenia | 1 | 2005 | 48 | 0.060 |
Why?
|
| Myocardium | 2 | 2008 | 1045 | 0.060 |
Why?
|
| Tachycardia | 1 | 2005 | 70 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2005 | 72 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 2210 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 68 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 739 | 0.060 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 140 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3642 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2006 | 203 | 0.060 |
Why?
|
| Outpatients | 1 | 2006 | 267 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 223 | 0.060 |
Why?
|
| Cause of Death | 1 | 2007 | 504 | 0.060 |
Why?
|
| Probability | 2 | 2019 | 335 | 0.050 |
Why?
|
| Biopsy | 2 | 2023 | 1300 | 0.050 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 110 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 122 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 50 | 0.050 |
Why?
|
| Obesity | 2 | 2021 | 2411 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2005 | 245 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 71 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2005 | 313 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 268 | 0.050 |
Why?
|
| Hirudins | 1 | 2022 | 40 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 814 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 176 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 28 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2021 | 881 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 57 | 0.050 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 62 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 693 | 0.050 |
Why?
|
| Thinness | 1 | 2021 | 77 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2023 | 243 | 0.050 |
Why?
|
| Hemolysis | 1 | 2021 | 113 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2005 | 566 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 224 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1484 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 146 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 131 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 1437 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 508 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1193 | 0.040 |
Why?
|
| Quality of Life | 2 | 2020 | 2139 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1734 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 1464 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 832 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 225 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 478 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 833 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 599 | 0.030 |
Why?
|
| Public Health | 1 | 2019 | 287 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1154 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1907 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 500 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2019 | 490 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1969 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2016 | 38 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 578 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3840 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 197 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1603 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2009 | 1596 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 365 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 722 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2013 | 13 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 240 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2013 | 68 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 561 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2008 | 522 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 4551 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 180 | 0.030 |
Why?
|
| Candida | 1 | 2013 | 83 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1094 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 485 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 825 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 79 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 376 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 113 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2008 | 72 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 139 | 0.020 |
Why?
|
| Assisted Circulation | 1 | 2007 | 37 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 294 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 658 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 236 | 0.020 |
Why?
|
| Stroke | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 341 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 261 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 198 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2008 | 452 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2008 | 193 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 133 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 453 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Papillary Muscles | 1 | 2005 | 21 | 0.020 |
Why?
|
| Warfarin | 1 | 2006 | 125 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 433 | 0.010 |
Why?
|
| Aspirin | 1 | 2006 | 231 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2005 | 115 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 777 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2008 | 1189 | 0.010 |
Why?
|
| Exercise | 1 | 2009 | 865 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2161 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 255 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1729 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 834 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 889 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2007 | 886 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1033 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2548 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 29213 | 0.000 |
Why?
|